Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0705-0001 in Healthy Adults
NCT07029568Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0705-0001 in chronic systemic inflammation, sponsored by Novo Nordisk. Primary endpoints: Treatment Emergent Adverse Events and Area Under the Curve. Started Jun 2025; status: completed.
02
Drugs
NNC0705-0001
03
Conditions
chronic systemic inflammation
Beyond the preview
Go deeper on NCT07029568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07029568.